MARKET

ZVRA

ZVRA

Zevra Therapeutics Inc
NASDAQ
10.24
+0.04
+0.39%
Closed 19:59 05/20 EDT
OPEN
10.30
PREV CLOSE
10.20
HIGH
10.51
LOW
10.16
VOLUME
1.03M
TURNOVER
0
52 WEEK HIGH
13.16
52 WEEK LOW
7.16
MARKET CAP
605.34M
P/E (TTM)
5.05
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at ZVRA last week (0511-0515)?
Weekly Report · 2d ago
Did One-Off-Boosted Q1 Profits Just Shift Zevra Therapeutics' (ZVRA) Investment Narrative?
Simply Wall St · 5d ago
A Look At Zevra Therapeutics (ZVRA) Valuation After Strong Earnings And SDX Portfolio Sale
Simply Wall St · 05/14 07:51
Weekly Report: what happened at ZVRA last week (0504-0508)?
Weekly Report · 05/11 09:40
Zevra Therapeutics Earnings Call Highlights Growth Pivot
TipRanks · 05/11 00:22
Analysts Are Bullish on These Healthcare Stocks: Zevra Therapeutics (ZVRA), CG Oncology, Inc. (CGON)
TipRanks · 05/08 20:20
Zevra Therapeutics (ZVRA) Is Up 8.2% After Debt-Free Turnaround And Rare Disease Refocus – What’s Changed
Simply Wall St · 05/08 18:46
Zevra Therapeutics Is Maintained at Buy by Guggenheim
Dow Jones · 05/08 13:39
More
About ZVRA
Zevra Therapeutics, Inc. is a commercial-stage rare disease company combining science, data, and patient need to create transformational therapies for diseases with limited or no treatment options. It has a diverse portfolio of products and product candidates, which includes pre-clinical, clinical, and commercial stage assets. Its active commercial products and development assets include MIPLYFFA, OLPRUVA, Celiprolol, KP1077IH, KP1077N and AZSTARYS. MIPLYFFA (arimoclomol) is its approved therapy for the treatment of Niemann-Pick disease type C (NPC). OLPRUVA (sodium phenylbutyrate) is its treatment for the treatment of certain urea cycle disorders (UCDs). Celiprolol is its investigational clinical candidate for the treatment of Vascular Ehlers-Danlos Syndrome (VEDS). KP1077 is its product candidate intended for the treatment of rare sleep disorders. KP1077N is a clinical development candidate for narcolepsy. AZSTARYS is for the treatment of attention deficit and hyperactivity disorder.

Webull offers Zevra Therapeutics Inc stock information, including NASDAQ: ZVRA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ZVRA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ZVRA stock methods without spending real money on the virtual paper trading platform.